Latest stories on CGEM
Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset
Seeking Alpha63 · neutralanalyst
Cullinan, Taiho say results of Phase 3 trial selected for presentation
The Fly63 · neutralproduct/pr
UBS raises Cullinan Oncology stock price target to $27 on trial data
Investing.com Analyst Ratings63 · neutralanalyst
Taiho, Cullinan Therapeutics study demonstrates statistically significant PFS
The Fly67 · bullishproduct/pr
Cullinan Therapeutics price target raised to $47 from $46 at Clear Street
The Fly62 · neutralanalyst
CGEM’s Zipalertinib Trial Meets Key Progression-Free Survival Mark, Paving Way for Possible FDA Filing
August 13, 2026
MarketChameleon73 · bullishproduct/pr
Cullinan rises as lung cancer drug succeeds in late-stage trial
Seeking Alpha73 · bullishproduct/pr
Why is Cullinan Oncology stock surging today?
Investing.com Markets63 · neutralgeneral
Cullinan Therapeutics, Inc. (CGEM) files 8-K
SEC 8-K50 · neutralgeneral
Cullinan Therapeutics, Inc. (CGEM) files 8-K
SEC 8-K50 · neutralgeneral
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Business Insider56 · neutralearnings
Cullinan Therapeutics stock rises on FDA meeting for CLN-049
Investing.com Markets63 · neutralgeneral
Why is Cullinan Therapeutics stock climbing today?
Investing.com Markets55 · neutralgeneral
Hong Kong’s property market set to cool despite run of record-breaking deals
SCMP42 · neutralgeneral
Cullinan Therapeutics, Inc. (CGEM) files 8-K
SEC 8-K50 · neutralgeneral
Cullinan Therapeutics: Heading Toward Paydirt
Seeking Alpha73 · bullishproduct/pr
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases Transcript
Seeking Alpha67 · bullishproduct/pr
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases - Slideshow
Seeking Alpha67 · bullishproduct/pr
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data
TipRanks67 · bullishproduct/pr
Cullinan Therapeutics, Inc. (CGEM) files 8-K
SEC 8-K50 · neutralgeneral
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data
TipRanks67 · bullishproduct/pr